Hematological and Biochemical Safety of Monthly Lokivetmab in Indian Dogs with Moderate to Severe Atopic Dermatitis
Résumé
Aims: To evaluate the hematological and biochemical safety profile of lokivetmab in client-owned dogs diagnosed with moderate to severe canine atopic dermatitis (CAD) over a 90-day treatment period. Study Design: Prospective, longitudinal clinical safety study. Place and Duration of Study: Teaching Veterinary Clinical Complex, College of Veterinary and Animal Sciences, Mannuthy, Thrissur, Kerala Veterinary and Animal Sciences University (KVASU), India, between July 2024 and February 2025. Methodology: Eight client-owned dogs with moderate to severe CAD were selected for the therapeutic study. All the eight animals were administered with lokivetmab injections (subcutaneously) (2 mg/kg) on Days 0, 30 and 60. Hematological and serum biochemical parameters were assessed on Day 0 and Day 90 of therapy and compared with healthy control dogs. Hematological parameters included packed cell volume (PCV), red blood cell (RBC) count, total and differential leukocyte counts. Biochemical assessments included blood urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), alkaline phosphatase (ALP), total protein (TP), albumin and globulin. Statistical comparisons were made using one-way ANOVA and paired t-tests. Results: Hemoglobin levels remained stable. PCV increased significantly from 33.88 ± 2.02 per cent to 42.49 ± 1.04 per cent (p = 0.05) and RBC counts improved from 5.09 ± 0.32 to 6.32 ± 0.26 million/μL (p = 0.09). WBC p=.04 (Day 90), granulocyte p=.04 (Day 0) and P= .02 (Day 90) and lymphocyte counts p=.01 (Day 0) and p=.04 (Day 90) showed significant improvement. Renal parameters remained stable. ALP p=.00 (Day 0) and p=.03 (Day 0) was significantly higher in CAD dogs at baseline (72.25 ± 17.95 IU/L) compared to controls (21.75 ± 4.80 IU/L; p = 0.02) but declined by Day 90. ALT p=.03 (Day 90) also decreased post-treatment. Total Protein, albumin and globulin increased modestly without statistical significance. No adverse events or side effects were reported during the study, supporting the safety profile of the intervention Conclusion: The hematological and biochemical safety of 90-day lokivetmab therapy is documented in Indian dogs with atopic dermatitis.